These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 16418810

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Optimization of the medical treatment for acromegaly].
    Díez JJ, Iglesias P.
    Med Clin (Barc); 2013 Apr 20; 140(8):360-5. PubMed ID: 23103101
    [Abstract] [Full Text] [Related]

  • 4. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G.
    Neuro Endocrinol Lett; 2008 Aug 20; 29(4):571-6. PubMed ID: 18766168
    [Abstract] [Full Text] [Related]

  • 5. Current pharmacotherapy for acromegaly: a review.
    Biermasz NR, Romijn JA, Pereira AM, Roelfsema F.
    Expert Opin Pharmacother; 2005 Nov 20; 6(14):2393-405. PubMed ID: 16259571
    [Abstract] [Full Text] [Related]

  • 6. Newer options in the management of acromegaly.
    Burt MG, Ho KK.
    Intern Med J; 2006 Jul 20; 36(7):437-44. PubMed ID: 16780450
    [Abstract] [Full Text] [Related]

  • 7. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 8. New perspectives in the medical treatment of acromegaly.
    Colao A, Pivonello R, Auriemma RS, Galdiero M, Guerra E, Milone F, De Leo M, Lombardi G.
    J Endocrinol Invest; 2005 May 12; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [Abstract] [Full Text] [Related]

  • 9. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R.
    J Clin Endocrinol Metab; 2006 Jan 12; 91(1):85-92. PubMed ID: 16263832
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Current treatment guidelines for acromegaly.
    Melmed S, Jackson I, Kleinberg D, Klibanski A.
    J Clin Endocrinol Metab; 1998 Aug 12; 83(8):2646-52. PubMed ID: 9709926
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    Hernandez I, Soderlund D, Espinosa-de-los-Monteros AL, Ochoa R, Zarate A, Mercado M.
    J Neurosurg; 1999 Apr 12; 90(4):647-50. PubMed ID: 10193608
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M.
    Eur J Endocrinol; 2014 Jan 12; 170(1):R31-41. PubMed ID: 24144967
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G.
    Eur J Endocrinol; 2006 Mar 12; 154(3):467-77. PubMed ID: 16498061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.